溢多利(300381) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 423,524,718.42, an increase of 6.57% compared to CNY 397,419,671.58 in the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 31,782,651.21, a decrease of 225.23% from a profit of CNY 25,379,143.78 in the previous year[4] - Total operating revenue for Q1 2022 was CNY 423,524,718.42, an increase of 6.3% compared to CNY 397,419,671.58 in the same period last year[20] - Net profit for Q1 2022 was a loss of CNY 26,818,163.79, compared to a profit of CNY 34,856,133.57 in Q1 2021[21] - The company reported a comprehensive income total of CNY -26,844,689.57 for Q1 2022, down from CNY 34,856,133.57 in the previous year[22] - Basic and diluted earnings per share for Q1 2022 were both CNY -0.0649, compared to CNY 0.0518 and CNY 0.0511 respectively in Q1 2021[22] Cash Flow - The net cash flow from operating activities increased by 81.48% to CNY 110,618,733.78, up from CNY 60,953,891.69 in the same period last year[4] - Cash inflow from operating activities was CNY 488,078,976.30 in Q1 2022, compared to CNY 423,530,749.89 in the same period last year[24] - Cash outflow from operating activities totaled CNY 377,460,242.52 in Q1 2022, an increase from CNY 362,576,858.20 in Q1 2021[24] - The net cash flow from investing activities was ¥180,684,992.34, a significant recovery from a negative cash flow of ¥79,495,187.00 in the same period last year[25] - Cash inflow from financing activities totaled ¥329,900,000.00, compared to ¥313,000,000.00 in Q1 2021, indicating a 5.8% increase[25] - The net cash flow from financing activities was negative at -¥104,538,178.62, contrasting with a positive cash flow of ¥1,616,608.43 in Q1 2021[25] - The total cash and cash equivalents at the end of Q1 2022 reached ¥438,443,224.76, up from ¥236,084,025.61 in Q1 2021, marking an increase of 85.6%[25] - The company reported cash inflow from the disposal of subsidiaries amounting to ¥202,574,000.00, which was not present in the previous year[25] - The cash outflow for the acquisition of fixed assets and intangible assets was ¥22,341,321.27, a decrease from ¥79,148,585.00 in Q1 2021, indicating a reduction of 71.8%[25] - The cash flow from financing activities included cash paid for debt repayment of ¥393,840,000.00, compared to ¥294,307,520.00 in Q1 2021, reflecting a 33.8% increase[25] - The impact of exchange rate changes on cash and cash equivalents was minimal, with a net effect of ¥1,982.73 in Q1 2022[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,559,922,469.13, reflecting a 1.79% increase from CNY 4,479,934,615.27 at the end of the previous year[4] - The company's total liabilities amounted to CNY 1,536,330,412.65 as of Q1 2022, compared to CNY 1,431,927,024.77 in the previous year[18] - Total equity attributable to shareholders was CNY 2,763,973,304.31 in Q1 2022, down from CNY 2,792,803,878.46 in Q1 2021[18] - The company reported a decrease in retained earnings to CNY 595,378,922.76 in Q1 2022 from CNY 627,161,573.96 in the previous year[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,526[12] - The largest shareholder, Zhuhai Jindadi Investment Co., Ltd., holds 30.97% of shares, totaling 151,767,378 shares, with 10,152,284 shares pledged[12] Operating Costs - Operating costs increased by 36.31% to CNY 312,995,478.94, primarily due to rising prices of chemical raw materials and fixed costs from new production facilities[8] - Total operating costs for Q1 2022 were CNY 455,142,026.86, up 26.5% from CNY 360,000,528.84 in Q1 2021[20] Other Income and Expenses - The company received government subsidies amounting to CNY 5,323,860.23, contributing to a 50.53% increase in other income[8] - The company reported a significant increase in other payables by 366.97% to CNY 179,605,480.97, mainly due to received deposits for the transfer of pharmaceutical segment equity[7] Stock and Incentive Plans - The company approved the sale of all assets related to its biopharmaceutical business, including shares of three subsidiaries[13] - The company adjusted the stock incentive plan, reducing the grant price from ¥5.06 to ¥4.99 per share[13] - The company granted 800,000 reserved shares to 22 incentive objects as part of the stock incentive plan[13] Audit Information - The company did not conduct an audit for the Q1 2022 report[26]